NCT05061095

Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

Completed Results posted Last updated 27 December 2024

What this trial tests

trial testing Assessment Surveys in Hematologic Neoplasms in 51 participants. Completed in 26 September 2023.

Timeline

21 March 2022

Primary endpoint
26 September 2023

26 September 2023

Quick facts

Lead sponsor	UNC Lineberger Comprehensive Cancer Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	51
Start date	21 March 2022
Primary completion	26 September 2023
Estimated completion	26 September 2023
Sites	1 location across United States

Drugs / interventions tested

• Assessment Surveys
• Qualitative Interviews

Conditions studied

• Hematologic Neoplasms — all drugs for Hematologic Neoplasms →

Sponsor

UNC Lineberger Comprehensive Cancer Center — full company profile →

Who can join

60 and older, any sex, with Hematologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Content Validity of Best-Worst Scaling (BWS) Survey Primary · 3 months after treatment decision

Cognitive interviewing will be used to evaluate the content validity of using a BWS survey to quantify the preferences of older patients with hematologic malignancies at the point-of-care. BWS survey asks patients a series of questions where they choose one attribute as best and one as worst - the 7 included in this survey are maintaining usual activities, living longer, avoiding dependence on others, avoiding short-term side effects, avoiding long-term side effects, avoiding hospitalizations, and avoiding high out-of-pocket costs.

Participants who were able to accurately define each attribute and reported no missing domains.

Group	Value	95% CI
Qualitative Interviews	10

Participants who could not define attributes or reported missing domains.

Group	Value	95% CI
Qualitative Interviews	0

Acceptability of Best-Worst Scaling (BWS) Survey to Patients Secondary · Up to 7 days after treatment decision

Number of patients who respond with agree/strongly agree to "I found survey acceptable to clarify my preferences"

Group	Value	95% CI
Pilot Testing: Participants With Newly-diagnosed Hematologic Malignancies	13

Preliminary Efficiency of Best-Worst Scaling (BWS) Survey Secondary · Up to 7 days after treatment decision

Number of patients who respond moderately effective/very affective to "how effective was the survey to help you and your doctor choose a treatment that was consistent with your goals?"

Group	Value	95% CI
Pilot Testing:	9

Completion Rate Over Time Secondary · Up to 1 year

The completion rate over time will be reported by the number of patients who complete the BWS survey at each time point, in 3 months intervals.

consented

Group	Value	95% CI
All Participants	51

started BWS instrument at baseline

Group	Value	95% CI
All Participants	27

completed BWS instrument at baseline

Group	Value	95% CI
All Participants	26

completed study-associated surveys after their treatment encounter at least 1 time

Group	Value	95% CI
All Participants	19

completed study-associated surveys after their treatment encounter more than 1 time (median 8 times)

Group	Value	95% CI
All Participants	16

Sponsor's own description

This study will evaluate the validity of using a survey to quantify patient preferences at the point-of-care and the potential effectiveness of the survey to improve goal-concordant care. The primary hypothesis is that by identifying the strength of patient preferences for outcomes with this survey clinicians will be able to improve goal-concordant care by aligning clinical recommendations with patients' preferences. This study will have 50 patients with newly diagnosed hematologic malignancy complete the survey throughout their disease course (up to 2 years) and conduct qualitative interviews with a subset (n = 20) of participants. The information obtained from these participants will be used to refine the survey. Interviews with oncologists and palliative care specialists (up to 10) will inform implementation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM.
   Richardson DR, Deal AM, Mhina CJ, Washko M, et al · · 2026 · PMID 42137489 · DOI 10.1177/23814683261440935